UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL							
OMB Number:	3235-0287						
Estimated average	burden						
hours per response	0.5						

longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response:	s)														
1. Name and Address of Reporting Person *- GOLDBERG DAVID C				2. Issuer Name and Ticker or Trading Symbol ENZO BIOCHEM INC [ENZ]						I	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (give title below) Other (specify below) VP CorpDev IGM Enz Clin Labs					
(Last) (First) (Middle) C/O ENZO BIOCHEM, INC., 527 MADISON AVE				3. Date of Earliest Transaction (Month/Day/Year) 01/17/2014						_X(
(Street)				4. If Amendment, Date Original Filed(Month/Day/Year)						_X_ Fo:	6. Individual or Joint/Group Filing(Check Applicable Line) X_Form filed by One Reporting Person Form filed by More than One Reporting Person					
	EW YORK, NY 10022															
(City	y)	(State)	(Zip)				Tab	le I - Non-D	eriva	tive Securities .	Acquired, I	Disposed of	f, or Benefi	cially Owne	d	
(Instr. 3)		2. Transaction Date (Month/Day/Yea	ır) any		n Date, if Co		ransaction le str. 8)	(A)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Owned Following Reported Transaction(s)		,	6. Ownership Form:	7. Nature of Indirect Beneficial	
				(Mor	ıth/Γ	Day/Year)		Code V	Amo	ount (A) or (D) F	(Instr.	(Instr. 3 and 4)			Direct (D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)
Reminder:	Report on a s	separate line for each	n class of securities b	eneficial	lly o	wned dire	ectly								I and	1454 (0.00)
								in this	s for	who respond to mare not requiy y valid OMB o	uired to re	spond ur				1474 (9-02)
			Table I							l of, or Benefic ertible securitie		1				
1. Title of Derivative Security (Instr. 3)	Conversion	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		(Month/Day/Year)			7. Title and Amount of Underlying Securities (Instr. 3 and 4)			9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s	Owners Form of Derivat Security Direct (or Indir	Beneficia Ownershi (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable		Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	(Instr. 4)
Stock Option (to acquire common stock)	\$ 2.7	01/17/2014		A		29,455		01/17/201	5(1)	01/17/2019	Common Stock	29,455	\$ 0	29,455	D	
Repor	ting O	wners														

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
GOLDBERG DAVID C C/O ENZO BIOCHEM, INC. 527 MADISON AVE NEW YORK, NY 10022			VP CorpDev IGM Enz Clin Labs				

Signatures

/s/ David C. Goldberg	01/22/2014
**Signature of Reporting Person	Date

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The Reporting Person was granted 29,455 options. The Options have a five year term which shall vest in three equal installments commencing on January 17, 2015.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.